BridgeBio Pharma (NASDAQ:BBIO) Director Sells $150,579.72 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Hannah Valantine sold 2,196 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $68.57, for a total transaction of $150,579.72. Following the sale, the director owned 9,259 shares in the company, valued at approximately $634,889.63. The trade was a 19.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hannah Valantine also recently made the following trade(s):

• On Monday, June 22nd, Hannah Valantine sold 2,808 shares of BridgeBio Pharma stock. The shares were sold at an average price of $68.00, for a total transaction of $190,944.00.

BridgeBio Pharma Trading Up 0.8%

Shares of NASDAQ BBIO opened at $70.24 on Friday. The company has a fifty day moving average price of $68.88 and a 200 day moving average price of $71.82. The firm has a market cap of $13.76 billion, a PE ratio of -18.78 and a beta of 0.97. BridgeBio Pharma, Inc. has a 1-year low of $41.80 and a 1-year high of $84.94.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.14). The business had revenue of $194.51 million during the quarter, compared to analysts’ expectations of $178.07 million. BridgeBio Pharma’s revenue for the quarter was up 66.8% on a year-over-year basis. During the same quarter last year, the company earned ($0.88) earnings per share. Equities research analysts forecast that BridgeBio Pharma, Inc. will post -2.29 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on BBIO shares. Royal Bank Of Canada initiated coverage on BridgeBio Pharma in a research note on Thursday, April 9th. They issued an “outperform” rating and a $100.00 target price on the stock. Raymond James Financial downgraded shares of BridgeBio Pharma from an “outperform” rating to a “market perform” rating in a report on Tuesday, May 26th. Weiss Ratings reissued a “sell (d)” rating on shares of BridgeBio Pharma in a research report on Friday, May 15th. Leerink Partners restated an “outperform” rating and set a $98.00 target price on shares of BridgeBio Pharma in a report on Thursday, March 12th. Finally, Mizuho decreased their target price on shares of BridgeBio Pharma from $106.00 to $96.00 and set an “outperform” rating for the company in a research report on Tuesday, June 16th. Twenty-one research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $92.90.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Jones Financial Companies Lllp bought a new position in shares of BridgeBio Pharma in the 1st quarter valued at about $35,000. First Trust Advisors LP lifted its position in BridgeBio Pharma by 200.4% during the second quarter. First Trust Advisors LP now owns 263,693 shares of the company’s stock worth $11,386,000 after acquiring an additional 175,918 shares during the last quarter. Baird Financial Group Inc. boosted its holdings in shares of BridgeBio Pharma by 1.8% during the second quarter. Baird Financial Group Inc. now owns 42,057 shares of the company’s stock worth $1,816,000 after acquiring an additional 731 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new position in shares of BridgeBio Pharma in the second quarter valued at approximately $1,650,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of BridgeBio Pharma by 2.4% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 95,326 shares of the company’s stock worth $4,132,000 after purchasing an additional 2,206 shares during the period. Institutional investors and hedge funds own 99.85% of the company’s stock.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.